Kimia Farma Tbk PT
IDX:KAEF

Watchlist Manager
Kimia Farma Tbk PT Logo
Kimia Farma Tbk PT
IDX:KAEF
Watchlist
Price: 600 IDR Market Closed
Market Cap: 3.3T IDR
Have any thoughts about
Kimia Farma Tbk PT?
Write Note

Kimia Farma Tbk PT
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kimia Farma Tbk PT
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Kimia Farma Tbk PT
IDX:KAEF
Note Receivable
Rp3B
CAGR 3-Years
-22%
CAGR 5-Years
-2%
CAGR 10-Years
8%
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kalbe Farma Tbk PT
IDX:KLBF
Note Receivable
Rp130.7B
CAGR 3-Years
61%
CAGR 5-Years
36%
CAGR 10-Years
26%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Note Receivable
Rp9.7B
CAGR 3-Years
15%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Soho Global Health Tbk PT
IDX:SOHO
Note Receivable
Rp755m
CAGR 3-Years
-83%
CAGR 5-Years
-61%
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kimia Farma Tbk PT
Glance View

Market Cap
3.3T IDR
Industry
Pharmaceuticals

PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.

KAEF Intrinsic Value
1 038.26 IDR
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Kimia Farma Tbk PT's Note Receivable?
Note Receivable
3B IDR

Based on the financial report for Sep 30, 2024, Kimia Farma Tbk PT's Note Receivable amounts to 3B IDR.

What is Kimia Farma Tbk PT's Note Receivable growth rate?
Note Receivable CAGR 10Y
8%

Over the last year, the Note Receivable growth was -22%. The average annual Note Receivable growth rates for Kimia Farma Tbk PT have been -22% over the past three years , -2% over the past five years , and 8% over the past ten years .

Back to Top